Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02711956 · ClinicalTrials.gov registry record · Phase 1

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Zenith Epigenetics.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target
8
Study locations

NCT02711956: Completed Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Zenith Epigenetics.

NCT02711956 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by Zenith Epigenetics. The registered enrollment target is 75 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02711956, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by Zenith Epigenetics.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target
8
Study locations

Study Summary

This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

Primary Outcome

Determination of DLT was made during the first 28 days of treatment in the dose escalation phase. A DLT is defined as a clinically significant AE or laboratory abnormality that is considered possibly, probably, or definitely related to study drug. The MTD reflects the highest dose of ZEN003694 in combination with enzalutamide that did not cause a DLT in more than 1 of 6 patients. The RP2D is the recommended dose of ZEN003694 in combination with enzalutamide as determined in the dose confirmation

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Enzalutamide
  • DRUG ZEN003694

Study Locations (8)

California

  • University of California Los Angeles Medical Center - Los Angeles
  • University of California San Francisco Medical Center - San Francisco

Michigan

  • Karmanos Cancer Institute - Detroit
  • Karmanos Cancer Institute - Farmington Hills

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Weill Cornell Medicine - New York Presbyterian - New York

Oregon

  • Oregon Health & Science University - Portland

Washington

  • Seattle Cancer Care Alliance - Seattle

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2016-12
Est. Completion 2019-11
Phase Phase 1
Zenith Epigenetics

4 total trials

What the finished NCT02711956 record still lists

NCT02711956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT02711956 lists 8 locations in 5 states (California, Michigan, New York).

Frequently Asked Questions

What is clinical trial NCT02711956 about?

NCT02711956 is a clinical study titled "A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer". This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

What is the current status of trial NCT02711956?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2016-12. Estimated completion is 2019-11.

What conditions does trial NCT02711956 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT02711956?

The interventions under investigation include: Enzalutamide (DRUG), ZEN003694 (DRUG).

Who is sponsoring clinical trial NCT02711956?

This trial is sponsored by Zenith Epigenetics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02711956 being conducted?

This trial has 8 study locations across California, Michigan, New York, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02711956's enrollment target sits among peer trials

75 33rd of 69 higher than 36 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02711956, the US trial registry maintained by the National Library of Medicine. NCT02711956 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.